---
title: "GAD: It is expected that the net profit in 2025 will be between 3.2 million yuan and 4.8 million yuan, turning a profit compared to the previous year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274298953.md"
description: "GAD announced that it expects a net profit of RMB 3.2 million to RMB 4.8 million for the fiscal year 2025, compared to a net loss of RMB 22.1914 million in the same period last year. The expected net profit growth is between 114.42% and 121.63%. During the reporting period, the company continued to strengthen the collection of accounts receivable, and the recognized credit impairment losses significantly decreased compared to the same period last year; at the same time, it deepened expense control, resulting in a decrease in period expenses compared to the same period last year"
datetime: "2026-01-30T11:23:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274298953.md)
  - [en](https://longbridge.com/en/news/274298953.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274298953.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274298953.md) | [繁體中文](https://longbridge.com/zh-HK/news/274298953.md)


# GAD: It is expected that the net profit in 2025 will be between 3.2 million yuan and 4.8 million yuan, turning a profit compared to the previous year

GAD announced that it expects a net profit of between 3.2 million and 4.8 million yuan for the fiscal year 2025, compared to a net loss of 22.1914 million yuan in the same period last year. The expected net profit growth is between 114.42% and 121.63%. During the reporting period, the company continued to strengthen its efforts in collecting accounts receivable, resulting in a significant decrease in the provision for credit impairment losses compared to the same period last year; at the same time, it deepened expense control, with this period's operating expenses decreasing compared to the same period last year

### Related Stocks

- [GAD (300902.CN)](https://longbridge.com/en/quote/300902.CN.md)

## Related News & Research

- [Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst⢠(bumetanide nasal spray)](https://longbridge.com/en/news/281570860.md)
- [TGI Research by Axina Group Sub of TGI Announces "AFRICA RISING 2026" | TSPG Stock News](https://longbridge.com/en/news/281420922.md)
- [Phú Mỹ Hưng links with banks to offer low rates to customers](https://longbridge.com/en/news/281592062.md)
- [MAN launches Lion’s City E production in Ankara](https://longbridge.com/en/news/281533213.md)
- [ZAWYA: Sharjah Collection unveils exclusive Homat Al Watan offer across its distinctive retreats](https://longbridge.com/en/news/281513097.md)